RadNet, Inc. (NASDAQ:RDNT) Director Lawrence L. Levitt sold 8,811 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $10.82, for a total value of $95,335.02. Following the completion of the sale, the director now owns 190,126 shares in the company, valued at $2,057,163.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

RadNet, Inc. (NASDAQ:RDNT) opened at 11.00 on Friday. RadNet, Inc. has a 52-week low of $5.25 and a 52-week high of $11.50. The company’s 50-day moving average price is $9.49 and its 200 day moving average price is $7.45. The stock has a market capitalization of $519.93 million, a P/E ratio of 57.89 and a beta of 0.92.

RadNet (NASDAQ:RDNT) last issued its earnings results on Tuesday, August 8th. The medical research company reported $0.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.07. The business had revenue of $230.00 million for the quarter, compared to analysts’ expectations of $230.32 million. RadNet had a return on equity of 19.98% and a net margin of 1.04%. The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.09 EPS. On average, equities research analysts anticipate that RadNet, Inc. will post $0.30 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Lawrence L. Levitt Sells 8,811 Shares of RadNet, Inc. (RDNT) Stock” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/22/lawrence-l-levitt-sells-8811-shares-of-radnet-inc-rdnt-stock.html.

Several analysts have recently issued reports on the company. TheStreet upgraded RadNet from a “c” rating to a “b-” rating in a research report on Thursday, August 24th. BidaskClub upgraded RadNet from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 24th. Finally, Jefferies Group LLC upgraded RadNet from a “hold” rating to a “buy” rating and upped their price objective for the company from $7.00 to $12.00 in a research report on Tuesday, August 22nd. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $9.63.

Several institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of RadNet by 7.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,531,850 shares of the medical research company’s stock worth $11,872,000 after buying an additional 112,194 shares during the period. Vanguard Group Inc. boosted its position in shares of RadNet by 4.2% in the second quarter. Vanguard Group Inc. now owns 1,284,852 shares of the medical research company’s stock worth $9,957,000 after buying an additional 51,229 shares during the period. Robotti Robert boosted its position in shares of RadNet by 0.8% in the first quarter. Robotti Robert now owns 748,416 shares of the medical research company’s stock worth $4,416,000 after buying an additional 6,100 shares during the period. State Street Corp boosted its position in shares of RadNet by 9.2% in the second quarter. State Street Corp now owns 585,218 shares of the medical research company’s stock worth $4,538,000 after buying an additional 49,186 shares during the period. Finally, Northern Trust Corp boosted its position in shares of RadNet by 5.2% in the second quarter. Northern Trust Corp now owns 436,407 shares of the medical research company’s stock worth $3,382,000 after buying an additional 21,746 shares during the period. 48.81% of the stock is owned by institutional investors and hedge funds.

About RadNet

RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.

Insider Buying and Selling by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Stock Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related stocks with our FREE daily email newsletter.